At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Paludrine + Folic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Jobelyn ( Extract of Sorghum Bicolor) on the Haematological Parameters of Patients With Sickle Cell Anaemia Disease.
In Brief
A Phase 2 clinical trial evaluating Paludrine + Folic Acid and Paludrine + Folic Acid + Jobelyn for Sickle Cell Anemia. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The primary objective is to determine if there is a significant increase in the haematocrit value of patients on Jobelyn and standard therapy compared to those on standard therapy alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Anemia
CountriesNigeria
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
Primary CompletionMar 2012
Study CompletionAug 2012
First PostedOct 2012
TodayJul 2026
First PostedOct 10, 2012
Enrollment StartJan 1, 2012
Primary CompletionMar 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.7 years ago
Interventions
Paludrine + Folic Aciddrug
This is the combination of routine drugs for treating sickle cell disease
Paludrine + Folic Acid + Jobelyndietary
Combination of routine drugs + Jobelyn